The Management of Early Alzheimer's Disease : Biological and Technological Advances.

Format:

Book

Author/Creator:

Chan, Dennis.

Language:

English

Physical Description:

1 online resource (426 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2025.

Summary:

Early Detection of Alzheimer's Disease: Biological and Technological Advances aims to introduce to a wide audience the high global priority problem of detecting AD prior to dementia onset.

Contents:

Front Cover

The Management of Early Alzheimer's Disease

Copyright

Contents

Contributors

1 - Introduction

References

2 - A century of Alzheimer's disease: Merging neuropathology with in vivo biomarkers

Overview

The modern beginning of "Alzheimer's disease"

The era of clinical-pathological correlation

The rise of genetics and the molecular biology of AD

Challenges to the status quo

The advent of biomarkers

The research framework and a biological definition of AD

Challenges to the research framework

With a view to the future

3 - Early Alzheimer's disease: Clinical overview

Alzheimer's disease pathology

Early Alzheimer's disease pathology

Amyloid-beta

Tau

Co-pathology

The syndrome of mild cognitive impairment

Subjective cognitive decline

Mild behavioral impairment

Sub-classification mild cognitive impairment

Conversion to dementia

Management of mild cognitive impairment

Clinical assessment

Treatment

Pharmacological

Non-pharmacological

4 - The need for early diagnosis-Clinical, societal and health economic drivers

Epidemiology of dementia

The aging population - prevalence and incidence of dementia and dementia subtypes

Global time trends and inequalities in dementia prevalence and incidence

Risk factors

Dementia costs

Access to diagnosis

Future perspectives

Conclusion

5 - An overview of current diagnostic strategies

Neuropsychological testing

Screening tools

Cognitive domains testing

Functional assessment instruments

Diagnostic tools to support clinical diagnosis

Cerebrospinal fluid

Magnetic Resonance Imaging

Positron emission tomography imaging

Conclusions

References.

6 - Novel approaches to diagnosis

6a - Opportunities arising from the tech revolution

Introduction

Digital testing

App-based active testing

Passive sensing

Big data

Machine learning

Personalized diagnostics

Risks associated with usage of digital tools

6b - Advances in imaging

Neurodegeneration and MRI

Reserve and resilience

Brain reserve

Cognitive reserve

Structural traits

Synaptic dysfunction

Cerebrovascular imaging

Time of flight (TOF) imaging

Perfusion and permeability imaging

Glymphatic imaging

Perivascular spaces

Inferior frontal sulcal hyperintensities

White matter hyperintensities

Summary

6c - Advances in fluid-based biomarkers

Fluid biomarkers for Aβ pathology

Biomarkers for tau pathology

Fluid biomarkers for neurodegeneration

From research tools to clinical implementation

Limitations of fluid-based biomarkers

Biomarkers for AD-how can they be used in the most effective manner now that we have approved disease-modifying therapies?

Acknowledgments

Conflicts of interest

6d - Advances in cognitive testing

Novel cognitive tests sensitive to early Alzheimer's disease

Progression of AD pathology and the functional architecture of episodic memory and spatial navigation

Object memory

Feature binding and associative memory

Spatial memory and navigation

Comparison to current clinical standards

Digital cognitive assessments in Alzheimer's disease

In-clinic supervised digital cognitive assessments using tablets and personal computers

Remote unsupervised assessments using mobile devices in the home environment

High-frequency assessments to increase the diagnostic signal

Repeated assessments and novel test regimes

Practice effects.

Long-term memory and forgetting

Need for validation of novel digital assessments

Other approaches to infer cognitive status

7 - Challenges for the new approach

7a - Ethical challenges associated with the early detection of Alzheimer's disease

Early what?

The right to know and the consequences of early detection for the individual

The value of knowing (and knowing what)

The potential harms of predictive information

The social consequences of early detection

Stigma and discrimination

Justice and equity considerations

The future of early detection

Early detection and genetic risk

Expanding early detection and screening

7b - Privacy

Privacy issues

Types of adversaries

Privacy attacks and mitigation techniques

Re-identification attack-anonymization frameworks

Statistical inference attack

Privacy leaks in apps

Other privacy preserving systems

Conclusion and future directions

8 - An eye to the future

8a. Beyond diagnosis: how to use such approaches for intervention

8a(i) - Clinical trials

Early disease identification and the predictive value of biomarkers

A shift from late-stage clinical presentation to early disease detection

The Alzheimer's disease continuum

The neuropathology of Alzheimer's disease

Methods for investigating Alzheimer's disease pathology

Genetics

Current drugs development and past successes/failures

Symptomatic treatments: Past, present and future

Cognition and everyday function

Acetylcholinesterase inhibitors

NMDA receptor antagonist

α7 nicotinic receptor agonists and modulators

MAO-B inhibitors

11β-HSD1 inhibitors

Sleep

Disease modifying treatments: Past, present and future

Treatments targeting amyloid.

Treatments targeting tau

Treatments targeting other biomarkers

Future directions e.g., novel outcome measures

Measuring treatment success

Clinical meaningfulness in Alzheimer's disease outcomes

Electronic person specific outcome measure (ePSOM) development program

Computerized assessment methods

Clinical trials designs, considerations, major initiatives

Randomized control trials

Database discoveries

Platform trials

Stratified medicine

8a(ii) - Non-pharmacological interventions

Overview of risk and protective factors

Identification of "at risk" individuals

Non-pharmacological management strategies

Lifestyle interventions

Diet

Exercise

Multi-domain interventions

Psychological symptoms

Hearing impairment

Cognitive training/stimulation

Role of health and care professionals

Funding sources

8b - Next generation technologies for diagnosis

Advancing current approaches

Imaging

Optical markers

Behavioral markers

Virtual and augmented reality markers

Digital biomarkers

Artificial Intelligence

Direct brain technologies

What do we want?

Index

Back Cover.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9780128222416

0128222417

9780128222409

0128222409

OCLC:

1513423924